High Dose Cytosine Arabinoside for Acute Lymphoblastic Leukaemia
Author Information
Author(s): A.Z.S. Rohatiner, R. Bassan, R. Battista, M.J. Barnett, W. Gregory, J. Lim, J. Amess, A. Oza, T. Barbui, M. Horton, T. Chisesi, T.A. Lister
Primary Institution: ICRF Department of Medical Oncology, St Bartholomew's Hospital, London, UK
Hypothesis
Does incorporating high-dose cytosine arabinoside into treatment improve outcomes for adults with acute lymphoblastic leukaemia?
Conclusion
The addition of high-dose cytosine arabinoside did not improve overall survival or remission duration for all patients, but may benefit those with high-risk disease.
Supporting Evidence
- Complete remission was achieved in 36 out of 54 patients.
- Response correlated with younger age.
- Patients with high-risk disease showed improved prognosis with intensive therapy.
Takeaway
This study looked at whether a stronger medicine could help adults with a type of blood cancer. It found that while some patients did better, many did not see any improvement.
Methodology
Patients were treated with high-dose cytosine arabinoside as part of a modified treatment program and their responses were compared to historical controls.
Potential Biases
Potential bias due to the historical control group and the small number of patients.
Limitations
The study had a small sample size and comparisons were made with historical controls.
Participant Demographics
Patients aged 15-57, median age 32.
Statistical Information
P-Value
0.02
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website